These combined results lead us to speculate that VCAM-1-D6 huMab likely acts as a VCAM-1-D6-blocking antibody by binding to VCAM-1-D6, potentially altering its structure, and resulting in inhibition of VCAM-1-mediated signaling that is necessary for lung cancer cell invasion; however, further studies are required to address the precise binding and signaling effects of VCAM-1-D6 huMab. Here, VCAM1 is linked to lung carcinoma.